Today's episode of tHEORetically speaking features Gary Curhan, Chief Medical Officer and Jessica Paulus, Vice President of Research at OM1, as they answer questions on Leveraging Real-World Data for Precision Obesity Treatment.
In a talk at the Morgan Stanley healthcare conference this week, Eli Lilly’s CFO Anat Ashkenazi spoke about the company’s deliberations in deciding whether to split Tirzepatide into two brands, one for diabetes and one for obesity. Lilly has done this before with Prozac (fluoxetine), making a new brand for premenstrual dysphoric disorder. It did not do the same for the drug Cialis, an erectile dysfunction drug also indicated for benign prostatic hyperplasia.
Eli Lilly’s tirzepatide was recently approved for weight loss by the US FDA. A newly published study in the New England Journal of Medicine shows that the drug has similar effects to gastric bypass surgery. The data further supports the use of the drug to treat obesity, which is associated with conditions like cardiovascular disease, diabetes, and some cancers. Patients with a BMI 30 or greater that took the drug and got counseling for healthy eating and exercise lost 20.9% of their body weight in 72 weeks, compared to 3% body weight loss in the placebo group. This has big implications for patients, providers, and payers.